CAR-T cells leave the comfort zone: current and future applications beyond cancer [0.03%]
CAR-T细胞走出舒适区：当前及未来抗癌以外的前景与挑战
Mariana Torres Mazzi,Karina Lôbo Hajdu,Priscila Rafaela Ribeiro et al.
Mariana Torres Mazzi et al.
Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in the immunotherapy field and has achieved great success following its approval in 2017 for the treatment of B cell malignancies. While CAR-T cells are mostly applied...
Adrenergic signaling regulation of macrophage function: do we understand it yet? [0.03%]
肾上腺素信号调节巨噬细胞功能：我们了解清楚了吗？
Beatriz Marton Freire,Filipe Menegatti de Melo,Alexandre S Basso
Beatriz Marton Freire
Macrophages are immune cells that are widespread throughout the body and critical for maintaining tissue homeostasis. Their remarkable plasticity allows them to acquire different phenotypes, becoming able either to fight infection (M1-like,...
Current and future perspectives of chimeric antigen receptors against glioblastoma [0.03%]
嵌合抗原受体治疗胶质母细胞瘤的现状与未来展望
Josephine Zhang,Jesús A Siller-Farfán
Josephine Zhang
Glioblastoma multiforme (GBM) is the most malignant form of cancer in the central nervous system; even with treatment, it has a 5-year survival rate of 7.2%. The adoptive cell transfer (ACT) of T cells expressing chimeric antigen receptors ...
Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer [0.03%]
靶向自身免疫病、神经病变和癌症中的高亲和力受体FcγRI
Tosca Holtrop,Kevin Budding,Arianne M Brandsma et al.
Tosca Holtrop et al.
The Fc gamma receptor I (FcγRI or CD64) is the only human Fc receptor with a high affinity for monomeric IgG. It plays a crucial role in immunity, as it mediates cellular effector functions of antibodies including phagocytosis, antigen pre...
Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration [0.03%]
口服抗原可通过给药时间的不同来减少或加剧炎性关节病动物模型的病理变化
Gavin R Meehan,Hannah E Scales,Iain B McInnes et al.
Gavin R Meehan et al.
Currently, treatments for rheumatoid arthritis (RA) are focussed on management of disease symptoms rather than addressing the cause of disease, which could lead to remission and cure. Central to disease development is the induction of autoi...
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors [0.03%]
免疫检查点抑制剂诱导的逆向银屑病亚型的流行率
Abdulhadi Jfri,Bonnie Leung,Jordan T Said et al.
Abdulhadi Jfri et al.
Background: Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and flares, may occur. Evidence is lacking on invers...
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor [0.03%]
靶向TIM-3受体的新型免疫疗法Sabatolimab的特征化研究
Stephanie Schwartz,Nidhi Patel,Tyler Longmire et al.
Stephanie Schwartz et al.
Objectives: Sabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatol...
Liam V Brown,Jonathan Wagg,Rachel Darley et al.
Liam V Brown et al.
Drug development typically comprises a combination of pre-clinical experimentation, clinical trials, and statistical data-driven analyses. Therapeutic failure in late-stage clinical development costs the pharmaceutical industry billions of ...
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy [0.03%]
肥胖和脂肪组织对T细胞反应和癌症免疫检查点阻断治疗的影响
Gabriel Pasquarelli-do-Nascimento,Sabrina Azevedo Machado,Juliana Maria Andrade de Carvalho et al.
Gabriel Pasquarelli-do-Nascimento et al.
Many different types of cancer are now well known to have increased occurrence or severity in individuals with obesity. The influence of obesity on cancer and the immune cells in the tumor microenvironment has been thought to be a pleiotrop...
Natalie M Edner,Chun Jing Wang,Lina Petersone et al.
Natalie M Edner et al.
Curbing unwanted T cell responses by costimulation blockade has been a recognised immunosuppressive strategy for the last 15 years. However, our understanding of how best to deploy this intervention is still evolving. A key challenge has be...